CARIBOU BIOSCIENCES INC. - COMMON STOCK

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

08 May 2025 13:05:03 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

06 May 2025 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

24 Apr 2025 13:15:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

10 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

18 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

12 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

02 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

20 Nov 2024 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update

06 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

25 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

03 Sep 2024 05:01:11 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

26 Aug 2024 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

12 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

09 Jul 2024 05:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

02 Jun 2024 16:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

30 May 2024 13:01:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

07 May 2024 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 May 2024 13:05:00 By Nasdaq GlobeNewswire